(Q33291990)

English

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

Daniel Catovsky

1

object named as

D Catovsky

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Estella Matutes

3

object named as

E Matutes

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

8

object named as

T Hamblin

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

V. Brito-Babapulle

16

object named as

V Brito-Babapulle

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

author name string

S Richards

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

D Oscier

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

M J S Dyer

5

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

R F Bezares

6

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

A R Pettitt

7

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

D W Milligan

9

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

J A Child

10

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

M S Hamilton

11

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

C E Dearden

12

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

A G Smith

13

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

A G Bosanquet

14

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Z Davis

15

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

M Else

17

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

R Wade

18

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

P Hillmen

19

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group

20

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

NCRI Chronic Lymphocytic Leukaemia Working Group

21

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

language of work or name

0 references

publication date

1 July 2007

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

370

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

9583

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

230-239

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(07)61125-8

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33291990&oldid=1766308428"